OMG Antibodies
Polyclonal antibodies derived from tumor-infiltrating lymphocytes represent a new, off-the-shelf therapeutic platform that targets multiple tumor antigens to overcome cancer heterogeneity and immune escape.
Monoclonal antibodies have become a cornerstone of modern oncology, offering highly specific tumor targeting and therapeutic efficacy. However, a critical limitation of monoclonal antibody therapy is its narrow specificity: each antibody typically targets a single tumor antigen. Tumor cells, notorious for their adaptability, frequently evade these treatments through antigen loss, mutation, or shedding—mechanisms that allow them to escape immune detection and therapeutic pressure.
Additionally, while antibody engineering has produced functionally enhanced monoclonals (e.g., bispecifics, ADCs), these remain limited by their single-epitope targeting and patient-specific variability. Meanwhile, polyclonal antibodies such as intravenous immunoglobulins (IVIg) are successfully used in autoimmune disorders but have not been leveraged in oncology.
Recent insights into the role of tumor-infiltrating B cells and their antibodies suggest a natural, polyclonal immune response within the tumor microenvironment may carry untapped therapeutic potential. This invention emerges from that insight—transforming tumor-induced polyclonal antibodies into a universal, multi-epitope therapeutic platform.
Inventors
Dr. Alessio Nahmad
Prof. Salomon Stemmer
Prof. Gal Markel
Dr. Michal Besser
Contact info
Sari Prutchi Sagiv PhD Director of Pharma and Diagnostics
For further information please contact:
The invention introduces Oncologic Multi-Epitope General (OMG) antibodies, a new class of polyclonal antibodies derived from tumor-infiltrating B lineage cells. These antibodies are isolated by culturing patient-derived tumor-infiltrating lymphocytes under conditions that promote B cell differentiation into plasma cells, followed by purification of the secreted antibodies.
Unlike monoclonals, OMG antibodies recognize a wide range of tumor-associated antigens and epitopes, addressing tumor heterogeneity head-on. In advanced embodiments, these antibodies are genetically engineered (termed OMEGA antibodies) to include T-cell engager domains, cytokine fusions, or other anti-tumor functional elements—without altering their original tumor specificity.
The result is a library of antibodies capable of eliciting multifaceted immune responses across a variety of cancers. OMG/OMEGA antibodies may be used in autologous settings, shared among patients with the same malignancy, or pooled to create broadly effective “master batches.” Their production can be scaled using bioreactors, offering both personalized and off-the-shelf cancer therapies.
OMG antibodies represent a transformative opportunity in cancer immunotherapy, especially in the era of precision and combination oncology. By targeting multiple antigens simultaneously, they have the potential to prevent tumor escape mechanisms and be effective across heterogeneous tumor landscapes. This approach aligns with the growing interest in leveraging the tumor microenvironment and immune repertoire for therapeutic benefit.
With cross-tumor reactivity observed in some cases, the platform could be applicable not only in patient-specific therapy but also as a universal therapeutic across different cancer types. Furthermore, the ability to engineer these antibodies into functionally enhanced OMEGA variants opens the door to customizable immune modulators, akin to next-generation antibody-drug conjugates or bispecifics, but built on a polyclonal scaffold.
From a commercialization perspective, OMG antibodies offer scalable production methods, compatibility with current biomanufacturing platforms, and potential for intellectual property covering both the base polyclonal compositions and the engineered derivatives. The unmet need they address—tumor heterogeneity and immune escape—remains a major challenge in oncology, placing this innovation at the forefront of next-gen antibody therapeutics.